Vetter strikes out on new pathways to further develop the injection process

How can digital trends be used purposefully in regards to the application of injection systems? That is the key question being addressed by Vetter’s Open Innovation Challenge.

This new campaign, created by the Contract Development and Manufacturing Organization (CDMO) was officially launched at workshop in Ravensburg. The purpose of the challenge is to develop innovative, future-focused and sustainable solutions for the injection of medicines that are even better streamlined to user needs than current methods. Promising ideas emanating from the initiative will be further pursued in the context of Vetter’s innovation process.

The challenge consists of multi-disciplinary teams participating in workshops and field-work with the theme ꞌInjection 2.0ꞌ. Four groups comprising a total of 20 participants will include students, medical and economic professionals, and staff from the pharmaceutical service provider itself.

The initiative will apply ꞌDesign Thinkingꞌ, a user-centered innovation method that involves direct communication with actual users of injection systems, including professional caregivers and patients in an effort to create more purposeful injection processes. The campaign will continue until the end of September with the winning team receiving an award of EUR 10,000.

“As an innovative partner of the top 20 pharmaceutical and biotech companies worldwide, we feel it is our responsibility to introduce continuous improvements to the safety and comfort aspects of the injection process for users as well as enhancements to our service offering based around the injection of medicine. That is precisely what our Open Innovation Challenge is designed to do; benefit medical specialists and patients as well as offering our customers new and valuable insights,” said Dr. Claus Feussner, Senior Vice President Vetter Development Service.

In order to identify sustainable areas of innovation potential, the pharmaceutical service provider incorporates the Design Thinking method. The User-Centered Innovation (UCI) approach is based on direct integration of users from the first day of development work. For example, in the first field-work phase, participating teams will interview patients, doctors and professional caregivers in healthcare settings that include nursing homes, assisted living facilities, hospitals, and the home healthcare sector itself.

The goal is to use this information to address patient’s conscious and subconscious needs and any problems that arise when interacting with injection systems on a regular basis. Based on these results, user-oriented ideas for solutions can be generated.

“In the future, the active integration of users into the pharmaceutical development process will take on increasing importance. Because most users have long since arrived in the digital world, they are expecting to see this megatrend applied to medical products as well. That is why we have been investing today for the future, as demonstrated by our Open Innovation Challenge.

This initiative will not only strengthen our role as one of the world’s leading partners in the development and manufacture of injectable drugs, but also reinforce the competitive position of our clients in the global market,” said Oskar Gold, Vetter’s Senior Vice President Key Account Management, Marketing/Corporate Communications and Customer Project Management.

Vetter is conducting the Open Innovation Challenge in cooperation with the bwcon Innovation Academy. bwcon GmbH is one of Europe’s leading technology networks, bringing together approximately 600 companies and research establishments.

Find the Vetter press kit, additional press releases, high-resolution pictures and more background information in our Download Center.

About Vetter
Headquartered in Ravensburg, Germany, Vetter is a global leading contract development and manufacturing organization (CDMO) with production facilities in Germany and the United States. The company, which currently employs 4,400 individuals worldwide, has long-term experience offering services ranging from early development support including clinical manufacturing, to commercial supply and various packaging solutions for vials, syringes and cartridges. Vetter’s customers range from small and midsize to the world’s top 20 pharmaceutical and biotech companies. As a leading solution provider, the CDMO recognizes its responsibility in supporting the needs of its customers in developing devices that contribute to increased patient safety, convenience, and enhanced compliance. In addition, the company places high importance on social responsibility including environmental protection and sustainability. Learn more about Vetter at www.vetter-pharma.com.